RE:Re:What is the plan!!!Gilles is 'The Delivery Man' because he delivers. With absolutely epic timing he acquired AEZS's assets at the bottom of the historic biotech bear market for less than cash value. AEZS's pipeline targets markets in the billions-of-dollars and AEZS's diagnostic is just before expected approval for its target pediatric market. This acquisition also delivered CZO to NASDAQ and the TSX ahead of key defining events. Gilles has delivered the avenanthramide pill to the point of a human trial and safety/tolerability and preliminary efficacy data is coming as part of the Phase I/IIa clinical trial. PGX has been delivered to its first approved product expected by the end of the year as the decision point for mass industrialization is expected to be commissioned in Q3. Gilles called the wound healing results with the Angiogenesis Foundation a 'home run' and it should be completing its study shortly. PGX-YBG data he been sent to the peer-review journal Biomaterials and Dr. Martin Kolb previously said that if preclinical results are replicated it could profoundly alter the treatment landscape.
Gilles is 'The Delivery Man'...
